NCT05093478View on ClinicalTrials.gov

The Prevalence of Local Immunoglobulin E (IgE) Elevation and Its Effect on Intranasal Capsaicin Therapy in the Non-allergic Rhinitis Population

PHASE3CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

September 10, 2019

Primary Completion Date

November 30, 2023

Study Completion Date

November 30, 2023

Conditions
Non-allergic Rhinitis
Interventions
DRUG

Intranasal capsaicin

Intranasal capsaicin, 5 applications each delivering 2 micrograms in each nostril, separated by 1 hour.

DRUG

topical lidocaine

The nose will be pre-treated with topical lidocaine 15 minutes before each application

Trial Locations (1)

77030

The University of Texas Health Science Center at Houston, Houston

All Listed Sponsors
collaborator

American Academy of Otolaryngic Allergy

OTHER

lead

The University of Texas Health Science Center, Houston

OTHER

NCT05093478 - The Prevalence of Local Immunoglobulin E (IgE) Elevation and Its Effect on Intranasal Capsaicin Therapy in the Non-allergic Rhinitis Population | Biotech Hunter | Biotech Hunter